| Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma M Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, ... New England Journal of Medicine 357 (21), 2123-2132, 2007 | 1819 | 2007 |
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ... Journal of clinical oncology 27 (32), 5410, 2009 | 849 | 2009 |
| Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma H Quach, D Ritchie, AK Stewart, P Neeson, S Harrison, MJ Smyth, ... Leukemia 24 (1), 22-32, 2010 | 738 | 2010 |
| Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, ... J Clin Oncol 30 (6), 631-636, 2012 | 735 | 2012 |
| Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United … EA Olsen, S Whittaker, YH Kim, M Duvic, HM Prince, SR Lessin, GS Wood, ... Journal of Clinical Oncology 29 (18), 2598, 2011 | 655 | 2011 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 621* | 2019 |
| Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ... The Lancet 390 (10094), 555-566, 2017 | 558 | 2017 |
| Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, ES Jaffe, ... Blood, The Journal of the American Society of Hematology 117 (22), 5827-5834, 2011 | 538 | 2011 |
| Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, ... Molecular Therapy 21 (11), 2122-2129, 2013 | 489 | 2013 |
| EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary … W Kempf, K Pfaltz, MH Vermeer, A Cozzio, PL Ortiz-Romero, M Bagot, ... Blood, The Journal of the American Society of Hematology 118 (15), 4024-4035, 2011 | 467 | 2011 |
| Breast implant–associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients RN Miranda, TN Aladily, HM Prince, R Kanagal-Shamanna, D De Jong, ... Journal of clinical oncology 32 (2), 114, 2014 | 447 | 2014 |
| Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation … A Spencer, HM Prince, AW Roberts, IW Prosser, KF Bradstock, L Coyle, ... J Clin Oncol 27 (11), 1788-1793, 2009 | 435 | 2009 |
| Clinical studies of histone deacetylase inhibitors HM Prince, MJ Bishton, SJ Harrison Clinical cancer research 15 (12), 3958-3969, 2009 | 432 | 2009 |
| Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and … JJ Scarisbrick, HM Prince, MH Vermeer, P Quaglino, S Horwitz, P Porcu, ... Journal of Clinical Oncology 33 (32), 3766, 2015 | 423 | 2015 |
| A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease MED Flowers, JF Apperley, K van Besien, A Elmaagacli, A Grigg, V Reddy, ... Blood, The Journal of the American Society of Hematology 112 (7), 2667-2674, 2008 | 401 | 2008 |
| Breast implant–associated anaplastic large cell lymphoma in Australia and New Zealand: high-surface-area textured implants are associated with increased risk A Loch-Wilkinson, KJ Beath, RJW Knight, WLF Wessels, M Magnusson, ... Plastic and reconstructive surgery 140 (4), 645-654, 2017 | 387 | 2017 |
| Bacterial biofilm infection detected in breast implant–associated anaplastic large-cell lymphoma H Hu, K Johani, A Almatroudi, K Vickery, B Van Natta, ME Kadin, G Brody, ... Plastic and reconstructive surgery 137 (6), 1659-1669, 2016 | 369 | 2016 |
| Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma L Ellis, Y Pan, GK Smyth, DJ George, C McCormack, R Williams-Truax, ... Clinical Cancer Research 14 (14), 4500-4510, 2008 | 346 | 2008 |
| Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study A Younes, A Sureda, D Ben-Yehuda, PL Zinzani, TC Ong, HM Prince, ... Journal of Clinical Oncology 30 (18), 2197-2203, 2012 | 318 | 2012 |
| Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia BJP Huntly, AG Reid, AJ Bench, LJ Campbell, N Telford, P Shepherd, ... Blood, The Journal of the American Society of Hematology 98 (6), 1732-1738, 2001 | 296 | 2001 |
